Home › Trials › NCT06668064

Evaluating EYP-1901 for treating wet age-related macular degeneration

A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Phase 3 Interventional EyePoint Pharmaceuticals, Inc. · NCT06668064

This study is testing if a new treatment called EYP-1901 can work better than the standard drug Aflibercept for people with wet age-related macular degeneration.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment400 (estimated)
Ages50 Years and up
SexAll
SponsorEyePoint Pharmaceuticals, Inc. Industry-sponsored
Drugs / interventionsbevacizumab, ranibizumab, faricimab
Locations81 sites (Phoenix, Arizona and 80 other locations)
Trial IDNCT06668064 on ClinicalTrials.gov

What this trial studies

This phase 3 interventional study is designed to compare the efficacy of EYP-1901, a tyrosine kinase inhibitor, against Aflibercept in patients with wet age-related macular degeneration (wAMD). The study will involve a randomized, double-masked approach to ensure unbiased results, with primary efficacy assessed at week 56. Participants will include both previously treated and treatment-naïve patients who meet specific visual acuity criteria. The goal is to determine if EYP-1901 can provide better outcomes than the current standard treatment.

Who should consider this trial

Good fit: Ideal candidates are patients with a documented diagnosis of wAMD and a specific range of visual acuity scores.

Not a fit: Patients with severe vision loss or certain types of eye damage, such as subfoveal fibrosis or scarring, may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer improved vision outcomes for patients suffering from wet age-related macular degeneration.

How similar studies have performed: Previous studies have shown promise with similar approaches, but the specific efficacy of EYP-1901 remains to be fully established.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit.
* Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellen equivalent) in the study eye at the Screening Visit and on Baseline (Day 1).
* For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.

Exclusion Criteria:

* Subfoveal fibrosis, atrophy, or scarring in the center subfield.
* BCVA using ETDRS charts \<20 letters (20/400 Snellen equivalent) in the fellow eye.

Where this trial is running

Phoenix, Arizona and 80 other locations

+31 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Wet Age Related Macular DegenerationwAMDWet Age-related Macular DegenerationTyrosine Kinase InhibitorEYP-1901EyePoint
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.